150
Participants
Start Date
June 1, 2020
Primary Completion Date
August 30, 2026
Study Completion Date
August 30, 2026
Induction with Brentuximab vedotin (BV)
3 cycles ESHAP plus antibody-drug conjugate brentuximab vedotin (BV) at a dose of 1.8 mg/kg IV
Induction without Brentuximab Vedotin
3 cycles of ESHAP as a standard of care therapy for those patients with primary refractory cHL and those patients relapsing after first-line therapy
Consolidation with Brentuximab Vedotin
Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days)
RECRUITING
Complexo Hospitalario Universitario A Coruña, A Coruña
RECRUITING
Hospital Universitario Virgen de Las Nieves, Granada
RECRUITING
Hospital General Universitario Gregorio Marañón, Madrid
RECRUITING
Hospital Ramón Y Cajal, Madrid
RECRUITING
Hospital Universitario Fundación Jiménez Díaz, Madrid
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Hospital General Universitario J.M. Morales Meseguer, Murcia
RECRUITING
Hospital Universitario Central de Asturias, Oviedo
RECRUITING
Hospital Universitario de Salamanca, Salamanca
RECRUITING
Hospital Universitario Marqués de Valdecilla, Santander
RECRUITING
Hospital Universitario Virgen Del Rocío, Seville
RECRUITING
Hospital Universitario Y Politécnico La Fe, Valencia
RECRUITING
Hospital Universitario de Cruces, Bilbao
RECRUITING
Institut Català D'Oncologia - Hospital Germans Trias I Pujol, Barcelona
RECRUITING
Hospital Clínic de Barcelona, Barcelona
RECRUITING
Hospital de La Santa Creu I Sant Pau, Barcelona
RECRUITING
Institut Català D'Oncologia - Hospital Duran I Reynals, Barcelona
RECRUITING
Institut Català D'Oncologia, Barcelona
RECRUITING
Hospital Clínico Universitario de Valencia, Valencia
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
OTHER